EUVIMEDObjevte EUVIMED
Crossref

Structure‐Based Design of 2‐Aminopyrazolpyrimidopyridone Derivatives as New Rearranged During Transfection ( RET ) Kinase Inhibitors

Jiayi Shen iD, Jihu Liu, Zhiyong Tan, Anzhi Li, Sheng Chen, Yongdong Li

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70039 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2025. Written by Jiayi Shen and 5 co-authors. Institution: Jiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, China. Major MEDLINE topics: Protein Kinase Inhibitors, Proto-Oncogene Proteins c-ret. Cited 1 times so far (Crossref); 27 references. Funded by: Natural Science Foundation of Jiangxi Province, National Natural Science Foundation of China, Doctor Foundation of Gannan Normal University.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

RET (Rearranged during transfection) kinase is a validated target for non‐small cell lung cancer (NSCLC). In 2020, two selective RET inhibitors, selpercatinib and pralsetinib were approved by the US FDA. However, high treatment costs and clinically acquired resistance (e.g., G810C/S/R) become the new challenges for RET‐based therapies. In this work, we discovered a series of 2‐aminopyrazolpyrimidopyridone RET inhibitors to overcome the V804M and G810C resistant mutations. One of the compounds, 8w , exhibited inhibitory potency against the BaF3 cells harboring CCDC6‐RET V804M mutation with an IC50 value of 0.715 μM. The compound also dose‐dependently suppressed the activation of RET and downstream signals. Another compound, 8s suppressed BaF3 cells harboring CCDC6‐RET G810C mutation with an IC 50 value of 2.91 μM. However, the poor solubility of these compounds will limit their further development. Therefore, compound 8w and 8s might be promising lead compounds for the development of novel RET V804M and RET G810C inhibitors overcoming the clinically acquired resistance.

Subjects

MeSH terms (MEDLINE)

Protein Kinase InhibitorsProto-Oncogene Proteins c-retHumansDrug DesignCell Line, TumorStructure-Activity RelationshipPyridonesAnimalsMolecular Docking SimulationMiceMutationPyrazolesCarcinoma, Non-Small-Cell LungPyrimidines

Author keywords

inhibitorsnon‐small cell lung cancer (NSCLC)rearranged during transfection (RET) kinaseresistance

Substances

Protein Kinase InhibitorsProto-Oncogene Proteins c-retPyridonesPyrazolesPyrimidines

Authors and institutions

  • Jiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, China.
  • Jiangxi ChiralSyn Biological Medicine Co. Ltd, Nanchang, China.

ORCID profiles: Jiayi Shen

Funding

  • Natural Science Foundation of Jiangxi Province
  • National Natural Science Foundation of China
  • Doctor Foundation of Gannan Normal University

Cite

APA

Shen, J., Liu, J., Tan, Z., Li, A., Chen, S., & Li, Y. (2025). Structure‐Based Design of 2‐Aminopyrazolpyrimidopyridone Derivatives as New Rearranged During Transfection ( RET ) Kinase Inhibitors. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70039

Vancouver

Shen J, Liu J, Tan Z, Li A, Chen S, Li Y. Structure‐Based Design of 2‐Aminopyrazolpyrimidopyridone Derivatives as New Rearranged During Transfection ( RET ) Kinase Inhibitors. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70039

BibTeX
@article{Shen2025,
  author = {Shen, Jiayi and Liu, Jihu and Tan, Zhiyong and Li, Anzhi and Chen, Sheng and Li, Yongdong},
  title = {Structure‐Based Design of 2‐Aminopyrazolpyrimidopyridone Derivatives as New Rearranged During Transfection ( RET ) Kinase Inhibitors},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70039}
}
Start for free →